replimune tudriqev - Search News

FDA approves Replimune's Tudriqev melanoma drug on 3rd try

FDA approves Replimune's Tudriqev melanoma drug on third try

The agency had twice rejected the engineered viral therapy over concerns about the design of Replimune's clinical trial

Continue reading

· 5h · on MSN

Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling.

Fierce Pharma · 1d

UPDATED: Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

1d

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based ...

Broad label to address high unmet need in advanced melanomaReplimune will host conference call on August 6, 2026 at 4:30 p.m. ET. WOBURN, ...

1d

REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?

Replimune said the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV, previously known as RP1, in ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results